Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2021.734761 Oncology Retraction Retraction: ECT2 Increases the Stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer Frontiers Editorial Office * Frontiers Media SA, Lausanne, Switzerland

Edited and reviewed by: Giuseppe Giaccone, Cornell University, United States

*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org

This article was submitted to Gastrointestinal Cancers, a section of the journal Frontiers in Oncology

 19 07 2021 2021 11 734761 01 07 2021 01 07 2021 Copyright © 2021 Frontiers Editorial Office 2021 Frontiers Editorial Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Retraction of the Original Research Article ECT2 Increases the Stability of EGFR and Tumorigenicity by Inhibiting Grb2 Ubiquitination in Pancreatic Cancer By Wang J, Yang S, Min L, Zhu S, Guo S and Zhang S (2021). Front. Oncol. 10:589241. doi: 10.3389/fonc.2020.589241

The Journal and Authors retract the 8 February 2021 article cited above for the following reasons provided by the Authors:

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.